EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cyclin Inhibitors in Advanced Breast Cancer: Evaluation of Toxicity in Older Patients

Filipe Veiga, Mafalda Costa, Rafael Marques, Rita Aranha, Cecília Caramujo, Viktor Malyarchuk, Catarina Lopes Fernandes, Joana Basílio Leite, Marta Vilaça, Matilde Salgado, Mónica Pinho, Amanda Nobre Carvalho, Sara Pinho Moreira, Manuela Machado

Acta Médica Portuguesa · 2026-11-02 · 39 (11) · 706-709

DOI: 10.20344/amp.24690 ↗
AbstractBibliografische Angaben

Abstract

Cyclin-dependent kinase (CDK) 4/6 inhibitors have improved survival outcomes in advanced breast cancer. Real-world data on tolerability and effectiveness in older patients are still scarce. This retrospective study analyzed data from patients with advanced hormone receptor-positive and HER2-negative breast cancer receiving CDK4/6 inhibitors as first-line treatment from July 2017 to June 2024. The aim was to evaluate the toxicity and effectiveness of that therapy in older (≥ 65 years) patients. A total of 79 female patients were included, with a median age of 62 years, 39.2% were ≥ 65 years. Patients aged ≥ 75 years constituted 19.0% of the total sample. No statistically significant difference in toxicity rates was observed between patients aged ≥ 65 and < 65 (p = 0.078), but toxicity was significantly higher in patients ≥ 75 years compared to the remaining patients (p = 0.030). The incidence of grade ≥ 3 toxicity did not differ significantly between age groups. One-year progression-free survival was 71.0% in patients ≥ 65 and 64.6% in patients < 65 (p = 0.555), with a hazard ratio for progression/death of 0.63 (95% CI: 0.33 - 1.21, p = 0.168). Although there was a higher rate of overall toxicity among older patients, CDK4/6 inhibitors were well tolerated in this sample.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →